Commission Regulation (EU) 2015/1221

of 24 July 2015

amending Regulation (EC) No 1272/2008 of the European Parliament and of the Council on classification, labelling and packaging of substances and mixtures, for the purposes of its adaptation to technical and scientific progress

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/20061, and in particular Article 37(5) thereof,

Whereas:

(1)
Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains two lists of harmonised classification and labelling of hazardous substances. Table 3.1 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to Regulation (EC) No 1272/2008. Table 3.2 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Annex VI to Council Directive 67/548/EEC2.
(2)

Proposals for new or updated harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA, as well as on the comments received from the parties concerned, it is appropriate to introduce or update harmonised classification and labelling of certain substances by amending Annex VI to that Regulation.

(3)

With regard to the substance nitric acid … % (EC number: 231-714-2), new scientific data has been made available for the hazard class ‘acute toxicity’ which suggests that the classification for this hazard class as recommended in the RAC opinion, which is based on older data, might not be appropriate. Therefore, this hazard class should not be included in Annex VI to Regulation (EC) No 1272/2008 until RAC has issued an opinion on the new information, while all other classes covered by the earlier opinion should be included.

(4)

With regard to the substance phenol, dodecyl-, branched (EC number: 310-154-3), the RAC is in the process of adopting a new opinion for the specific concentration limits to be applied to the hazard class ‘toxic for reproduction’. Therefore, this hazard class should not be included in Annex VI to Regulation (EC) No 1272/2008 until that opinion is finalised.

(5)
Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks. In addition, a certain period of time will be necessary to allow suppliers to comply with the registration obligations resulting from the new harmonised classifications for substances classified as carcinogenic, mutagenic or toxic to reproduction, categories 1A and 1B (Table 3.1) and categories 1 and 2 (Table 3.2), or as very toxic to aquatic organisms which may cause long term effects in the aquatic environment, in particular with those set out in Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council3.
(6)

In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow the application of the new provisions at an earlier stage on a voluntary basis, suppliers should have the possibility of applying the new harmonised classifications and of adapting the labelling and packaging accordingly on a voluntary basis before the deadline for compliance.

(7)

The measures provided for in this Regulation are in accordance with the opinion of the Committee established under Article 133 of Regulation (EC) No 1907/2006,

HAS ADOPTED THIS REGULATION:

Article 1

Annex VI to Regulation (EC) No 1272/2008 is amended in accordance with the Annex to this Regulation.

Article 2

By way of derogation from Article 3(2), the harmonised classifications set out in Annex to this Regulation may be applied before the date referred to in Article 3(2).

Article 3

1.

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

2.

Article 1 shall apply in respect of substances and mixtures from 1 January 2017.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 24 July 2015.

For the Commission

The President

Jean-Claude Juncker

ANNEX

Part 3 of Annex VI to Regulation (EC) No 1272/2008 is amended as follows:

  1. (1)

    Table 3.1 is amended as follows:

    1. (a)

      the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:

      Index No

      International Chemical Identification

      EC No

      CAS No

      Classification

      Labelling

      Specific Conc. Limits, M-factors

      Notes

      Hazard Class and Category Code(s)

      Hazard statement Code(s)

      Pictogram, Signal Word Code(s)

      Hazard statement Code(s)

      Suppl. Hazard statement Code(s)

      007-004-00-1

      nitric acid … %

      231-714-2

      7697-37-2

      Ox. Liq. 2

      Skin Corr. 1A

      H272

      H314

      GHS03

      GHS05

      Dgr

      H272

      H314

      EUH071

      Skin Corr. 1A; H314: C ≥ 20 %

      Skin Corr. 1B; H314: 5 % ≤ C < 20 %

      Ox. Liq. 2; H272: C ≥ 99 %

      Ox. Liq. 3; H272: 99 % > C ≥ 65 %

      B

      015-003-00-2

      calcium phosphide; tricalcium diphosphide

      215-142-0

      1305-99-3

      Water-react. 1

      Acute Tox. 2

      Acute Tox. 3

      Acute Tox. 1

      Eye Dam. 1

      Aquatic Acute 1

      H260

      H300

      H311

      H330

      H318

      H400

      GHS02

      GHS06

      GHS05

      GHS09

      Dgr

      H260

      H300

      H311

      H330

      H318

      H400

      EUH029

      EUH032

      M = 100

      031-001-00-4

      gallium arsenide

      215-114-8

      1303-00-0

      Repr. 1B

      Carc. 1B

      STOT RE 1

      H360F

      H350

      H372 (respiratory and haematopoietic systems)

      GHS08

      Dgr

      H360F

      H350

      H372 (respiratory and haematopoietic systems)

      050-008-00-3

      tributyltin compounds, with the exception of those specified elsewhere in this annex

      —

      —

      Repr. 1B

      Acute Tox. 3

      Acute Tox. 4*

      STOT RE 1

      Skin Irrit. 2

      Eye Irrit. 2

      Aquatic Acute 1

      Aquatic Chronic 1

      H360FD

      H301

      H312

      H372**

      H315

      H319

      H400

      H410

      GHS08

      GHS06

      GHS09

      Dgr

      H360FD

      H301

      H312

      H372**

      H315

      H319

      H410

      *

      STOT RE 1; H372: C ≥ 1 %

      STOT RE 2; H373: 0,25 % ≤ C < 1 %

      Skin Irrit. 2; H315:C ≥ 1 %

      Eye Irrit. 2; H319:C ≥ 1 %

      M = 10

      A

      1

      603-102-00-9

      1,2-epoxybutane

      203-438-2

      106-88-7

      Flam. Liq. 2

      Carc. 2

      Acute Tox. 4*

      Acute Tox. 4*

      Acute Tox. 4*

      STOT SE 3

      Skin Irrit. 2

      Eye Irrit. 2

      H225

      H351

      H302

      H312

      H332

      H335

      H315

      H319

      GHS02

      GHS08

      GHS07

      Dgr

      H225

      H351

      H302

      H312

      H332

      H335

      H315

      H319

      603-197-00-7

      tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol

      403-640-2

      107534-96-3

      Repr. 2

      Acute Tox. 4

      Aquatic Acute 1

      Aquatic Chronic 1

      H361d***

      H302

      H400

      H410

      GHS08

      GHS07

      GHS09

      Wng

      H361d***

      H302

      H410

      M = 1

      M = 10

      606-054-00-7

      isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone

      —

      141112-29-0

      Repr. 2

      Aquatic Acute 1

      Aquatic Chronic 1

      H361d***

      H400

      H410

      GHS08

      GHS09

      Wng

      H361d***

      H410

      M = 10

      M = 100

      607-197-00-8

      nonanoic acid

      203-931-2

      112-05-0

      Skin Irrit. 2

      Eye Irrit. 2

      Aquatic Chronic 3

      H315

      H319

      H412

      GHS07

      Wng

      H315

      H319

      H412

      613-042-00-5

      imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole

      252-615-0

      35554-44-0

      Carc. 2

      Acute Tox. 3

      Acute Tox. 4

      Eye Dam. 1

      Aquatic Chronic 1

      H351

      H301

      H332

      H318

      H410

      GHS08

      GHS06

      GHS05

      GHS09

      Dgr

      H351

      H301

      H332

      H318

      H410

      M = 10

      613-057-00-7

      dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine

      216-474-9

      1593-77-7

      Repr. 2

      STOT RE 2

      Skin Corr. 1C

      Skin Sens. 1A

      Aquatic Acute 1

      Aquatic Chronic 1

      H361d

      H373 (liver)

      H314

      H317

      H400

      H410

      GHS08

      GHS05

      GHS07

      GHS09

      Dgr

      H361d

      H373 (liver)

      H314

      H317

      H410

      EUH071

      M = 1

      M = 1

      613-133-00-X

      etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole

      219-991-8

      2593-15-9

      Carc. 2

      Acute Tox. 4

      Skin Sens. 1

      Aquatic Acute 1

      Aquatic Chronic 1

      H351

      H302

      H317

      H400

      H410

      GHS08

      GHS07

      GHS09

      Wng

      H351

      H302

      H317

      H410

      M = 1

      M = 1

      613-149-00-7

      pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one

      405-700-3

      96489-71-3

      Acute Tox. 3

      Acute Tox. 3

      Aquatic Acute 1

      Aquatic Chronic 1

      H331

      H301

      H400

      H410

      GHS06

      GHS09

      Dgr

      H331

      H301

      H410

      M = 1 000

      M = 1 000

    2. (b)

      the following entries are inserted in accordance with the order of the entries set out in Table 3.1:

      Index No

      International Chemical Identification

      EC No

      CAS No

      Classification

      Labelling

      Specific Conc. Limits, M-factors

      Notes

      Hazard Class and Category Code(s)

      Hazard statement Code(s)

      Pictogram, Signal Word Code(s)

      Hazard statement Code(s)

      Suppl. Hazard statement Code(s)

      019-003-00-3

      potassium (E,E)-hexa-2,4-dienoate

      246-376-1

      24634-61-5

      Eye Irrit. 2

      H319

      GSH07

      Wng

      H319

      604-092-00-9

      phenol, dodecyl-, branched [1];

      phenol, 2-dodecyl-, branched;

      phenol, 3-dodecyl-, branched;

      phenol, 4-dodecyl-, branched;

      phenol, (tetrapropenyl) derivatives [2]

      310-154-3 [1]

      121158-58-5 [1]

      74499-35-7 [2]

      Skin Corr. 1C

      Aquatic Acute 1

      Aquatic Chronic 1

      H314

      H400

      H410

      GHS05

      GHS09

      Dgr

      H314

      H410

      M = 10

      M = 10

      606-148-00-8

      carvone (ISO);

      2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]

      d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]

      l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]

      202-759-5 [1]

      218-827-2 [2]

      229-352-5 [3]

      99-49-0 [1]

      2244-16-8 [2]

      6485-40-1 [3]

      Skin Sens. 1

      H317

      GHS07

      Wng

      H317

      606-149-00-3

      tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione

      —

      335104-84-2

      Repr. 2

      STOT RE 2

      Skin Sens. 1

      Aquatic Acute 1

      Aquatic Chronic 1

      H361d

      H373 (eyes, kidneys, liver)

      H317

      H400

      H410

      GHS08

      GHS07

      GHS09

      Wng

      H361d

      H373 (eyes, kidneys, liver)

      H317

      H410

      M = 100

      M = 10

      607-707-00-9

      fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate

      —

      71283-80-2

      STOT RE 2

      Skin Sens. 1

      Aquatic Acute 1

      Aquatic Chronic 1

      H373 (kidneys)

      H317

      H400

      H410

      GHS08

      GHS07

      GHS09

      Wng

      H373 (kidneys)

      H317

      H410

      M = 1

      M = 1

      607-708-00-4

      octanoic acid

      204-677-5

      124-07-2

      Skin Corr. 1C

      Aquatic Chronic 3

      H314

      H412

      GHS05

      Dgr

      H314

      H412

      607-709-00-X

      decanoic acid

      206-376-4

      334-48-5

      Skin Irrit. 2

      Eye Irrit. 2

      Aquatic Chronic 3

      H315

      H319

      H412

      GHS07

      Wng

      H315

      H319

      H412

      607-710-00-5

      1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear

      271-093-5

      68515-50-4

      Repr. 1B

      H360FD

      GHS08

      Dgr

      H360FD

      607-711-00-0

      spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate

      —

      203313-25-1

      Repr. 2

      STOT SE 3

      Eye Irrit. 2

      Skin Sens. 1A

      Aquatic Acute 1

      Aquatic Chronic 1

      H361fd

      H335

      H319

      H317

      H400

      H410

      GHS08

      GHS07

      GHS09

      Wng

      H361fd

      H335

      H319

      H317

      H410

      M = 1

      M = 1

      607-712-00-6

      dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate

      250-778-2

      31717-87-0

      Repr. 2

      STOT RE 2

      Skin Corr. 1C

      Skin Sens. 1A

      Aquatic Chronic 1

      H361d

      H373 (liver)

      H314

      H317

      H410

      GHS08

      GHS05

      GHS07

      GHS09

      Dgr

      H361d

      H373 (liver)

      H314

      H317

      H410

      EUH071

      M = 1

      607-713-00-1

      fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate

      —

      134098-61-6

      Acute Tox. 3

      Acute Tox. 2

      Skin Sens. 1B

      Aquatic Acute 1

      Aquatic Chronic 1

      H301

      H330

      H317

      H400

      H410

      GHS06 GHS09

      Dgr

      H301

      H330

      H317

      H410

      M = 100

      M = 1 000

      607-714-00-7

      triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate

      —

      126535-15-7

      Carc. 2

      Aquatic Acute 1

      Aquatic Chronic 1

      H351

      H400

      H410

      GHS08

      GHS09

      Wng

      H351

      H410

      M = 100

      M = 10

      607-715-00-2

      bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate

      442-820-5

      149877-41-8

      STOT RE 2

      Skin Sens. 1

      Aquatic Acute 1

      Aquatic Chronic 1

      H373

      H317

      H400

      H410

      GHS08

      GHS07

      GHS09

      Wng

      H373

      H317

      H410

      M = 1

      M = 1

      613-319-00-0

      imidazole

      206-019-2

      288-32-4

      Repr. 1B

      Acute Tox. 4

      Skin Corr. 1C

      H360D

      H302

      H314

      GHS08

      GHS07

      GHS05

      Dgr

      H360D

      H302

      H314

      613-320-00-6

      lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione

      218-499-0

      2164-08-1

      Carc. 2

      Aquatic Acute 1

      Aquatic Chronic 1

      H351

      H400

      H410

      GHS08

      GHS09

      Wng

      H351

      H410

      M = 10

      M = 10

      616-213-00-2

      mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide

      —

      374726-62-2

      Aquatic Acute 1

      Aquatic Chronic 1

      H400

      H410

      GHS09

      Wng

      H410

      M = 1

      M = 1

      616-214-00-8

      metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide

      —

      139528-85-1

      Carc. 2

      STOT RE 2

      Aquatic Acute 1

      Aquatic Chronic 1

      H351

      H373 (eyes, kidneys)

      H400

      H410

      GHS08

      GHS09

      Wng

      H351

      H373 (eyes, kidneys)

      H410

      M = 1 000

      M = 100

      616-215-00-3

      dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide

      —

      163515-14-8

      Acute Tox. 4

      Skin Sens. 1

      Aquatic Acute 1

      Aquatic Chronic 1

      H302

      H317

      H400

      H410

      GHS07

      GHS09

      Wng

      H302

      H317

      H410

      M = 10

      M = 10

      616-216-00-9

      flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide

      —

      158062-67-0

      Acute Tox. 4

      H302

      GHS07

      Wng

      H302

      616-217-00-4

      sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide

      —

      946578-00-3

      Acute Tox. 4

      Aquatic Acute 1

      Aquatic Chronic 1

      H302

      H400

      H410

      GHS07

      GHS09

      Wng

      H302

      H410

      M = 1

      M = 1

  2. (2)

    Table 3.2 is amended as follows:

    1. (a)

      the entries corresponding to index numbers 007-004-00-1, 015-003-00-2, 031-001-00-4, 050-008-00-3, 603-102-00-9, 603-197-00-7, 606-054-00-7, 607-197-00-8, 613-042-00-5, 613-057-00-7, 613-133-00-X, and 613-149-00-7 are replaced by the following corresponding entries:

      Index No

      International Chemical Identification

      EC No

      CAS No

      Classification

      Labelling

      Concentration Limits

      Notes

      007-004-00-1

      nitric acid … %

      231-714-2

      7697-37-2

      O; R8

      C; R35

      O; C

      R: 8-35

      S: (1/2-)26-28- 36/37/39-45-63

      O; R8: C ≥ 65 %

      C; R35: C ≥ 20 %

      C; R34: 5 % ≤ C < 20 %

      B

      015-003-00-2

      calcium phosphide; tricalcium diphosphide

      215-142-0

      1305-99-3

      F; R15/29

      T+; R26/28

      Xn; R21

      R32

      Xi; R38-41

      N; R50

      F; T+; N

      R: 15/29-21-26/28-32-38-41-50

      S:(1/2-)26-28-30-36/37/39-43-45-60-61

      N; R50: C ≥ 0,25 %

      031-001-00-4

      gallium arsenide

      215-114-8

      1303-00-0

      Repr. Cat. 2; R60

      Carc. Cat. 2; R45

      T; R48/23

      T

      R: 45-48/23-60

      S: 45-53

      E

      050-008-00-3

      tributyltin compounds, with the exception of those specified elsewhere in this annex

      —

      —

      Repr. Cat. 2; R60-61

      T; R25-48/23/25

      Xn; R21

      Xi; R36/38

      N; R50-53

      T; N

      R: 21-25-36/38-48/23/25-50/53-60-61

      S: 45-53-60-61

      T; R25: C ≥ 2,5 %

      Xn; R22: 0,25 % ≤ C < 2,5 %

      Xn: R21: C ≥ 1 %

      T; R48/23/25: C ≥ 1 %

      Xn; R48/20/22: 0,25 % ≤ C < 1 %

      Xi; R36/38: C ≥ 1 %

      N; R50-53: C ≥ 2,5 %

      N; R51-53: 0,25 % ≤ C < 2,5 %

      R52-53: 0,025 % ≤ C < 0,25 %

      A

      1

      603-102-00-9

      1,2-epoxybutane

      203-438-2

      106-88-7

      F; R11

      Carc. Cat. 3; R40

      Xn; R20/21/22

      Xi; R36/37/38

      F; Xn

      R: 11-20/21/22-36/37/38-40-

      S: (2-)9-16-29-36/37-46

      603-197-00-7

      tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol

      403-640-2

      107534-96-3

      Repr. Cat. 3; R63

      Xn; R22

      N; R50-53

      Xn; N

      R: 22-50/53-63

      S: (2-)22-36/37-60-61

      N; R50-53: C ≥ 25 %

      N; R51-53: 2,5 % ≤ C <25 %

      R52-53: 0,25 % ≤ C < 2,5 %

      606-054-00-7

      isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl-p-tolyl ketone

      —

      141112-29-0

      Repr. Cat. 3; R63

      N; R50-53

      Xn; N

      R: 50/53-63

      S: (2-)36/37-60-61

      N; R50-53: C ≥ 2,5 %

      N; R51-53: 0,25 % ≤ C < 2,5 %

      R52-53: 0,025 % ≤ C < 0,25 %

      607-197-00-8

      nonanoic acid

      203-931-2

      112-05-0

      Xi; R36/38

      N; R51-53

      Xi; N

      R: 36/38-51/53

      S: (2-)46-61

      613-042-00-5

      imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole

      252-615-0

      35554-44-0

      Carc. Cat. 3; R40

      Xn; R20/22

      Xi; R41

      N; R51-53

      Xn; N

      R: 20/22-40-41-51/53

      S: (2-)26-36/37/39-46-61

      613-057-00-7

      dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine

      216-474-9

      1593-77-7

      Repr. Cat. 3; R63

      C; R34

      R43

      N; R50-53

      C; N

      R: 34-43-50/53-63

      S: (1/2-)26-28-36/37/39-45-60-61

      C; R34: C ≥ 10 %

      Xi; R36/37/38: 5 % ≤ C < 10 %

      N; R50-53: C ≥ 25 %

      N; R51-53: 2,5 % ≤ C < 25 %

      R52-53: 0,25 % ≤ C < 2,5 %

      613-133-00-X

      etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole

      219-991-8

      2593-15-9

      Carc. Cat. 3; R40

      Xn; R22

      R43

      N; R50-53

      Xn; N

      R: 22-40-43-50/53

      S: (2-)36/37-46-60-61

      N; R50-53: C ≥ 25 %

      N; R51-53: 2,5 % ≤ C < 25 %

      R52-53: 0,25 % ≤ C < 2,5 %

      613-149-00-7

      pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one

      405-700-3

      96489-71-3

      T; R23/25

      N; R50-53

      T; N

      R: 23/25-50/53

      S: (1/2-)36/37-45-60-61

      N; R50-53: C ≥ 0,025 %

      N; R51-53: 0,0025 % ≤ C < 0,025 %

      R52-53: 0,00025 % ≤ C < 0,0025 %

    2. (b)

      the following entries are inserted in accordance with the order of the entries set out in Table 3.2:

      Index No

      International Chemical Identification

      EC No

      CAS No

      Classification

      Labelling

      Concentration Limits

      Notes

      019-003-00-3

      potassium (E,E)-hexa-2,4-dienoate

      246-376-1

      24634-61-5

      Xi; R36

      Xi

      R: 36

      S: (2-)25-46

      604-092-00-9

      phenol, dodecyl-, branched [1];

      phenol, 2-dodecyl-, branched;

      phenol, 3-dodecyl-, branched;

      phenol, 4-dodecyl-, branched;

      phenol, (tetrapropenyl) derivatives [2]

      310-154-3 [1]-[2]

      121158-58-5 [1]

      74499-35-7 [2]

      C; R34

      N; R50-53

      C; N

      R: 34-50/53

      S: (1/2-)26-36/37/39-45-61

      N; R50-53: C ≥ 2,5 %

      N; R51-53: 0,25 % ≤ C < 2,5 %

      R52-53: 0,025 % ≤ C < 0,25 %

      606-148-00-8

      carvone (ISO);

      2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1]

      d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2]

      l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3]

      202-759-5 [1]

      218-827-2 [2]

      229-352-5 [3]

      99-49-0 [1]

      2244-16-8 [2]

      6485-40-1 [3]

      R43

      Xi

      R: 43

      S: (2-)24-37

      606-149-00-3

      tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione

      335104-84-2

      Repr. Cat. 3; R63

      Xn; R48/22

      R43

      N; R50-53

      Xn; N

      R: 43-48/22-50/53-63

      S: (2-)36/37-46-60-61

      N; R50-53: C ≥ 0,25 %

      N; R51-53: 0,025 % ≤ C < 0,25 %

      R52-53: 0,0025 % ≤ C < 0,025 %

      607-707-00-9

      fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate

      —

      71283-80-2

      Xn; R48/22

      R43

      N; R50-53

      Xn; N

      R: 43-48/22-50/53

      S: (2-)24-37-46-60-61

      N; R50-53: C ≥ 25 %

      N; R51-53: 2,5 % ≤ C < 25 %

      R52-53: 0,25 % ≤ C < 2,5 %

      607-708-00-4

      octanoic acid

      204-677-5

      124-07-2

      C; R34

      N; R51-53

      C; N

      R: 34-51/53

      S: (1/2-)26-36/37/39-45-61

      607-709-00-X

      decanoic acid

      206-376-4

      334-48-5

      Xi; R36/38

      N; R51-53

      Xi; N

      R: 36/38-51/53

      S: (2-)25-46-61

      607-710-00-5

      1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear

      271-093-5

      68515-50-4

      Repr. Cat. 2; R60-61

      T

      R: 60-61

      S: 53-45

      607-711-00-0

      spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate

      —

      203313-25-1

      Repr. Cat. 3; R62-63

      Xi; R36/37

      R43

      N; R50-53

      Xn; N

      R: 36/37-43-50/53-62-63

      S: (2-)36/37-60-61

      Xi; R43: C ≥ 0,1 %

      N; R50-53: C ≥ 25 %

      N; R51-53: 2,5 % ≤ C < 25 %

      R52-53: 0,25 % ≤ C < 2,5 %

      607-712-00-6

      dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate

      250-778-2

      31717-87-0

      Repr. Cat. 3; R63

      C; R34

      R43

      N; R51-53

      C; N

      R: 34-43-51/53-63

      S: (1/2-)26-28-36/37/39-45-61

      C; R34: C ≥ 10 %

      Xi: R36/37/38: 5 % ≤ C < 10 %

      607-713-00-1

      fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate

      —

      134098-61-6

      T+; R26

      Xn; R22

      R43

      N; R50-53

      T+; N

      R: 22-26-43-50/53

      S: (1/2-)28-36/37-45-60-61-63

      N; R50-53: C ≥ 0,25 %

      N; R51-53: 0,025 % ≤ C < 0,25 %

      R52-53: 0,0025 % ≤ C < 0,025 %

      607-714-00-7

      triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate

      —

      126535-15-7

      Carc. Cat. 3; R40

      N; R50-53

      Xn; N

      R: 40-50/53

      S: (2-)36/37-60-61

      N; R50-53: C ≥ 0,25 %

      N; R51-53: 0,025 % ≤ C < 0,25 %

      R52-53: 0,0025 % ≤ C < 0,025 %

      607-715-00-2

      bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate

      442-820-5

      149877-41-8

      R43

      N; R50-53

      Xi; N

      R: 43-50/53

      S: (2-)24-37-60-61

      N; R50-53: C ≥ 25 %

      N; R51-53: 2,5 % ≤ C < 25 %

      R52-53: 0,25 % ≤ C < 2,5 %

      613-319-00-0

      imidazole

      206-019-2

      288-32-4

      Repr. Cat 2; R61

      Xn; R22

      C; R34

      T; C

      R: 22-34-61

      S: 53-45

      613-320-00-6

      lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione

      218-499-0

      2164-08-1

      Carc. Cat. 3; R40

      N; R50-53

      Xn; N

      R: 40-50/53

      S: (2-)36/37-60-61

      N; R50-53: C ≥ 2,5 %

      N; R51-53: 0,25 % ≤ C < 2,5 %

      R52-53: 0,025 % ≤ C < 0,25 %

      616-213-00-2

      mandipropamid (ISO); 2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide

      —

      374726-62-2

      N; R50-53

      N

      R: 50/53

      S: 60-61

      N; R50-53: C ≥ 25 %

      N; R51-53: 2,5 % ≤ C <25 %

      R52-53: 0,25 % ≤ C < 2,5 %

      616-214-00-8

      metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide

      —

      139528-85-1

      Carc. Cat. 3; R40

      Xn; R48/22

      N; R50-53

      Xn; N

      R: 40-48/22-50/53

      S: (2-)36/37-46-60-61

      N; R50-53: C ≥ 0,025 %

      N; R51-53: 0,0025 % ≤ C < 0,025 %

      R52/53: 0,00025 % ≤ C < 0,0025 %

      616-215-00-3

      dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide

      —

      163515-14-8

      Xn; R22

      R43

      N; R50-53

      Xn; N

      R: 22-43-50/53

      S: (2-)24-37-60-61

      N; R50-53: C ≥ 2,5 %

      N; R51-53: 0,25 % ≤ C < 2,5 %

      R52-53: 0,025 % ≤ C < 0,25 %

      616-216-00-9

      flonicamid (ISO); N-(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide

      —

      158062-67-0

      Xn; R22

      Xn

      R: 22

      S: (2-)46

      616-217-00-4

      sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide

      —

      946578-00-3

      Xn; R22

      N; R50-53

      Xn; N

      R: 22-50/53

      S: (2-)60-61

      N; R50-53: C ≥ 25 %

      N; R51-53: 2,5 % ≤ C < 25 %

      R52-53: 0,25 % ≤ C < 2,5 %